Abstract: Primary brain tumours are heterogeneous in histology, genetics, and outcome. Although WHO's classification of tumours of the CNS has greatly helped to standardise diagnostic criteria worldwide, it does not consider the substantial progress that has been made in the molecular classification of many brain tumours. Recent practice-changing clinical trials have defined a role for routine assessment of MGMT promoter methylation in glioblastomas in elderly people, and 1p and 19q codeletions in anaplastic oligodendroglial tumours. Moreover, large-scale molecular profiling approaches have identified new mutations in gliomas, affecting IDH1, IDH2, H3F3, ATRX, and CIC, which has allowed subclassification of gliomas into distinct molecular subgroups with characteristic features of age, localisation, and outcome. However, these molecular approaches cannot yet predict patients' benefit from therapeutic interventions. Similarly, transcriptome-based classification of medulloblastoma has delineated four variants that might now be candidate diseases in which to explore novel targeted agents. Similarly, transcriptome-based classification of medulloblastoma has delineated four variants that may now be candidate diseases to explore novel targeted agents.
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Introduction
The World Health Organization (WHO) Classification of Tumours of the Central Nervous System distinguishes tumours by histological criteria and, based on morphological features of anaplasia, additionally allocates a malignancy grade ranging from WHO grade I to IV to each tumour, if applicable. Traditionally the nomenclature of brain tumours is often assigned based on a presumed cell of origin which is mainly deduced from cytological similarities of the tumour cells with the various normal cell types occuring in the central nervous system and its coverings (Webappendix). 1 From a historical perspective, histopathology thus was the first tool to distinguish brain tumors of different grades of malignancy and (presumed) different histogenetic origin, with the overall goal to provide clinicians with prognostic information. Histopathological classification alone has its limitations, but is greatly aided by immunohistochemical markers that help to discriminate different tumour entities with higher certainty, thereby reducing interobserver variability, and allow for a better characterization of novel tumour entities and variants. A next level of complexity is added by including molecular markers that carry both diagnostic and prognostic information in tumours with histologically similar appearance. Nevertheless, molecular markers have become an integral part of tumour grading and anatomo-pathological assessment in modern neuro-oncology practice because they provide useful information beyond the WHO classification, and molecular marker status now guides clinical decision making at least in subtypes of gliomas. 2 In parallel, several genome-or transcriptome-wide molecular approaches of brain tumour classification indicate that single marker profiling may only be a transient diagnostic standard which may soon be replaced at reasonable cost by tumour genome-wide molecular profiling techniques, including array-based methods as well as diagnostic next generation sequencing. The purpose of this review is to highlight recent advances in the molecular diagnosis and classification of primary brain tumours and to discuss how these advances inform therapeutic decisions.
Gliomas: single marker approaches

IDH mutation
Isocitrate dehydrogenase (IDH) mutations, 1p/19q co-deletions, and O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation are the three molecular markers that are currently assessed routinely in many brain tumour centres because of their diagnostic, prognostic, or predictive value (Table) . IDH mutations are early lesions in the development of gliomas and cluster in the active site of theses enzymes at codons 132 of the IDH1 respectively 172 of the IDH2 gene. The selective, heterozygous mutational targeting of specific sites of either gene seems necessary and sufficient for neoplastic transformation, suggesting that these mutations confer a gain of function and do not simply affect wildtype IDH function. They favour a neomorphic reaction catalysing the conversion of α-ketoglutarate into D-2-hydroxyglutarate, a candidate oncometabolite accumulating to high concentrations possibly measurable by MR spectroscopy in situ 3 and mediating the oncogenic activity of IDH mutations. 4 Most interestingly, IDH mutations have been reported to be causally linked to profound epigenetic changes, mediated by high concentrations of 2-hydroxyglutarate that inhibit α−ketoglutarate-dependent epigenetic modifiers such as tet methylcytosine dioxygenase (TET) 2, resulting in a glioma CpG island methylator phenotype (G-CIMP). 5 In addition, 2-hydroxyglutarate stimulates hypoxia-inducible factor (HIF) prolyl 4-hydroxylases (EGLN1. 2 and 3) which in turn leads to diminished HIF levels and enhances proliferation as well as soft agar growth of human astrocytes. 6 These insights provided evidence that gliomas with IDH mutations have a distinct pathogenetic origin.
Hence, the primary molecular approach to classify gliomas of adulthood is to separate gliomas into 26951 and Radiation Therapy Oncology Group (RTOG) 9402 -that explored the value of polychemotherapy using procarbacine, lomustin (CCNU) and vincristine (PCV) either prior to or immediately after RT indicate that the inclusion of chemotherapy in the first-line treatment confers a survival advantage which becomes evident after follow-up of more than six years rather specifically in the subgroup of patients with 1p/19q-co-deleted tumours (Table 2 ). Thus, 1p/19q co-deletions have also predictive value for benefit from chemotherapy, in addition to the characterization of a prognostically more favourable subgroup.
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The results from these studies led to the suspension of enrolment in the 3-arm CODEL trial which aimed at comparing RT plus temozolomide (TMZ) followed by TMZ (RT/TMZ →TMZ) with RT alone and TMZ alone. This is because RT alone was no longer considered an appropriate treatment for these patients. It has, however, to be noted that these results stem from retrospective analyses and are thus explorative, moreover, it remains unclear how many of the long-term survivors treated with RT plus PCV experience preserved cognitive function and quality of life. Finally, there is controversy whether the same improvement in overall survival could have been achieved with the combination of RT and TMZ or even with alkylating agent chemotherapy alone. The German NOA-04 trial which compared RT and TMZ or PCV alone 15 does not yet provide a conclusive answer regarding differences in long-term disease control with PCV versus TMZ since follow-up was too short at the time of initial publication. Yet, future clinical trials should probably include RT plus PCV polychemotherapy as a control arm.
MGMT promoter methylation
The DNA repair protein MGMT repairs the chemotherapy-induced alkylation at the O 6 -position of guanine, the critical mediator of alkylating agent cytotoxicity, and thus counteracts the effects of alkylating chemotherapeutic agents such as nitrosoureas or TMZ. Decreased MGMT protein levels are predicted to result in decreased ability of repair and therefore should be associated with improved outcome. Hypermethylation of the MGMT gene promoter may lead to silencing of the gene and thus decreased protein levels. Numerous clinical trials and cohort studies have shown that MGMT promoter methylation is associated with prolonged progression-free and overall survival in glioblastoma patients treated with alkylating agent chemotherapy. [16] [17] [18] [19] [20] [21] [22] In the pivotal trial establishing TMZ chemotherapy during and after radiotherapy in newly diagnosed glioblastoma, 23 the benefit from chemotherapy was almost exclusively attributable to patients with a methylated MGMT gene promoter. 18, 21 In 2012, two independent randomized trials conducted in elderly patients with anaplastic astrocytoma 24 Anaplastic gliomas, as opposed to the vast majority of primary glioblastomas, show distinct genetic and epigenetic aberration profiles implicating different pathomechanisms of tumourigenesis and progression. Somewhat unexpectedly, but at second thought not surprisingly, a specific predictive value of MGMT promoter methylation was not observed in two anaplastic glioma trials where patients were treated with RT versus alkylating chemotherapy alone 15 or with RT versus RT plus alkylating chemotherapy. 26 Nevertheless, a strong prognostic value of MGMT promoter methylation was demonstrated independent of the choice of initial therapy. While it was interesting to observe such a striking difference between anaplastic glioma and glioblastoma regarding the predictive role of MGMT promoter methylation, the biological basis of this phenomenon remains to be elucidated.
Interaction of various molecular markers
The three molecular markers described above are not entirely independent. 
Changing treatment paradigms based on biomarker assessment
Figures 1 and 2 summarize how the assessment of IDH, 1p/19q and MGMT status may be built into a management algorithm for patients with anaplastic gliomas and glioblastoma. Such algorithms are subject to change as new data and concepts emerge and may need to be adapted to institutional preferences. Importantly, the decision for specific treatments must take into account several issues such as patient preference, tumour location, volume of radiotherapy and potential comorbidities that might increase the risk of toxicity from chemotherapy. Figure 2 does not address the possible role of bevacizumab or other experimental treatments currently explored in the treatment of newly diagnosed glioblastoma.
ATRX mutations
The first evidence for a role of α-thalassemia/mental-retardation-syndrome-X-linked (ATRX) mutations in gliomas of various grades of malignancy was their association with alternative lengthening of telomeres. 30 It was then shown that ATRX mutations are associated with mutations of the TP53 and IDH1 genes across glioma entities. 11, 31 Most importantly, however, these same studies established ATRX mutations to be a very specific marker for astrocytic lineage tumours, including diffuse and anaplastic astrocytomas as well as a subset of oligoastrocytomas, positioning them as an attractive counterpart for 1p/19q co-deletions which appear to be mutually exclusive with ATRX mutations. Since the vast majority of mutations detected to date are truncating and thus lead to a reduction of protein levels, immunohistochemical demonstration of loss of ATRX may be a reasonable surrogate marker of ATRX mutations. Combining 1p/19q and ATRX assessments in a clinical setting may thus help in the future to guide the diagnosis within the spectrum of IDH-mutant gliomas and eventually to stratify patients for specific treatments.
H3F3A mutation
Employing exome-wide sequencing of pediatric glioblastomas and pontine gliomas, two recent studies identified frequent mutations in the histone H.3.3 gene (H3F3A). 32, 33 These mutations cluster at two critical amino acid residues, namely K27 and G34. Interestingly, the two H3F3A mutations appear to define distinct epigenetic subgroups of glioblastoma, with H3F3A (G34) mutant tumours showing global DNA hypomethylation. 34 Moreover, H3F3A mutations are mutually exclusive with IDH1 35 Collectively, all of these mutations (H3.3G34R/V and SETD2, and H3.3K27M) are believed to directly alter centrally important histone marks such as H3K36 trimethylation and H3.3K27 trimethylation, respectively.
EGFRvIII rearrangement
Approximately 25-30% of primary glioblastomas harbour a characteristic deletion mutant of the epidermal growth factor receptor (EGFR) gene referred to as EGFRvIII which results in constitutive and ligand-independent receptor activity and is considered an important oncogenic mutation. Its prognostic relevance remains controversial, but long-term survival may be inferior in patients whose tumours carry this mutation. EGFR-targeted approaches have not been effective in glioblastoma. 36 However, the EGFRvIII mutation also creates a new epitope which is immunogenic and thus a candidate tumour antigen in EGFRvIII-positive glioblastoma. Accordingly, vaccination strategies based on this unique peptide sequence have been developed and yielded promising overall survival results in various phase II trials which also provided preliminary evidence for target antigen elimination in recurrent tumours and a link between immune response to the vaccine and outcome. 37, 38 A placebo-controlled phase III trial, ACT IV, exploring the efficacy of the EGFRvIII-directed vaccine is currently enrolling patients. Finally, EGFRvIII mRNA has also been detected in microvesicles in the serum of patients with EGFRvIII-positive glioblastoma, 39, 40 indicating that it may serve as a biomarker to monitor response to therapy and detect relapse.
BRAF fusion or point mutation
Tandem duplications of BRAF at 7q34 resulting in KIAA1549:BRAF gene fusions, or sometimes alternative fusion partners, have been recognized as hallmark genetic lesions in pilocytic astrocytoma, with a particularly high incidence in cerebellar pilocytic astrocytomas. 41, 42 These fusions are only very rarely found in other tumours. KIAA1549:BRAF gene fusions are therefore considered a very important diagnostic aid to distinguish pilocytic astrocytoma from higher grade astrocytic tumours, a distinction that can be both challenging and therapeutically highly relevant given the fact that pilocytic astrocytomas and glioblastomas share the morphological feature of microvascular proliferation. Other genetic alterations of BRAF including point mutations, in particular the activating BRAF V600E missense mutation, have also been observed in low-grade gliomas as well as grade III/IV gliomas.
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BRAF V600E mutations are particularly common in pleomorphic xanthoastrocytomas, with two thirds of these tumours showing this aberration, which is nowadays easily demonstrated by immunohistochemistry using a mutation-specific antibody. 45 The glioma-associated BRAF alterations all exert their oncogenic activity by activating the mitogen-activated protein kinase (MAPK) pathway. 42 More recent studies employing large scale sequencing identified an oncogenic hit in the MAPK pathway in (almost) all pilocytic astrocytomas (Pfister, unpublished) while they did not reveal any significantly mutated gene outside of this pathway, indicating that this tumour may indeed be a single-pathway disease. The availability of small-molecule BRAF kinase inhibitors such as vemurafenib (PLX4032), which specifically targets BRAF V600E -mutant tumours, provides a new therapeutic approach to these subgroups of gliomas and preliminary clinical evidence (Pfister, unpublished) suggests that the presence of a BRAF V600E mutation may indeed serve as a potent predictive marker for this subset of patients across gliomas of various grades.
Gliomas: unbiased (high throughput) molecular diagnostic approaches
The notion that high throughput approaches of classifying brain tumours including gliomas are at least a valuable addition, if not superior to histopathological grading has been repeatedly supported in large datasets. However, due to the complexity in data analysis and interpretation, such techniques have not been introduced into clinical practice (yet). One of the first approaches was to define gene expression signatures derived from classical tumour samples and to use these as an aid to diagnose tumour samples that were less easily assigned to a specific diagnostic entity by histology alone. 46 Gene expression profiling of 276 gliomas resulted in the definition of 7 subgroups that did not simply reflect the histological diagnoses, but were prognostic, and correlated better with survival than histology. In fact, unsupervised bioinformatic clustering added to the prognostic information provided by histology whereas histology did not add to the information obtained by gene expression profiling. 47 The same approach was also applied to patients enrolled in EORTC 26951 13 and confirmed the prognostic value, moreover, it also allowed to identify a subgroup of patients who specifically benefitted from PCV chemotherapy. Superiority of gene expression profiling over 1p/19q testing, however, in predicting outcome was not demonstrated. 48 Gene expression profiling was also used to identify genes associated with outcome and let to the identification of candidate genes such as osteonectin, doublecortin, semaphorin 3B 49 or FABP7. 50 In a subpopulation of 80 glioblastomas from the EORTC/NCIC trial, 23 an expression signature dominated by HOX genes was associated with poor survival in patients treated with concomitant chemoradiotherapy, and both the HOX signature and EGFR expression were independent negative prognostic factors on multivariate analysis. 51 The poor prognostic value of the HOX gene-dominated stem cell related self-renewal signature was validated in an independent dataset of the same study. The functional association of the HOX gene signature with glioblastoma stem cells has been further substantiated and the negative prognostic effect was confirmed. kinase (88%), p53 (87%) and retinoblastoma protein (78%), 55 then, IDH mutations were discovered in a minority of glioblastoma patients which were young and had a good outcome, consistent with a secondary glioblastoma phenotype. 56 In 2010, a refined expression-based classification suggested the existence of four glioma subtypes: proneural, neural, classical and mesenchymal. 57 Gene expression patterns in these subgroups showed distinct correlations with those of oligodendrocytes, astrocytes, and neurons, providing possible clues to putative lineages of tumour origin. The authors also proposed differential benefit from therapy by subgroup, but these data need to be interpreted with caution, given the retrospective nature of this analysis and the heterogeneous treatments. Interestingly, annotation of the data set with the MGMT promoter methylation status revealed that none of the four subgroups displayed an association with the MGMT status. 28 Genome-wide DNA methylation profiling provided complementary information and most importantly uncovered the G-CIMP phenotype associated with IDH1 mutations. Interestingly, IDH-mutant and G-CIMP-positive tumours turned out to be a subgroup of the proneural subtype. 58 This discovery was instrumental for uncovering the mechanistic link between IDH mutations and genome-wide aberration of DNA methylation. 5 As detailed above, mutations in the histone H3 gene (H3F3A) were detected in more than a third of pediatric glioblastomas and more than two thirds of diffuse intrinsic pontine gliomas, further supporting the role of epigenetic deregulation in gliomagenesis. [31] [32] [33] [34] Accordingly, using Illumina 450K array-based methylation profiling, a novel subclassification of glioblastoma into 6 subgroups was proposed across age groups: the first three are linked to mutations of IDH or codons 27 or 34 of histone H3, which are mutually exclusive, the other groups were labelled receptor tyrosine kinase (RTK) I/PDGFRA, mesenchymal, and RTKII/classic. These six subclasses exhibited distinct profiles of age distribution, tumour localization, and outcome. 34 Importantly, this subclassification allowed to further split the proneural expression subgroups into basically four subgroups: IDH-mutant, H3F3A (K27)-mutant, H3F3A (G34)-mutant, and RTKI/PDGFRA. This is important since only the IDH group of proneural glioblastomas remains to be associated with a favourable prognosis, whereas the remaining patients do as poorly as or even worse than patients with mesenchymal, classic, or neural tumours. The clinical usefulness of these novel classifiers is currently being tested in prospective cohort studies.
Molecular classification of other primary brain tumours
Ependymal tumours
Ependymomas remain a domain for surgical and radiooncological treatment approaches whereas pharmacological strategies have remained largely disappointing, notably in adults. 59 Although there has been significant progress in the molecular characterization of these tumours as well, 60 and are genetically more unstable. These tumours are more prevalent in adults and located in the midline. 64 From a diagnostic perspective it is interesting that these two posterior fossa ependymoma subgroups may be distinguished immunohistochemically, with group A tumours expressing LAMA2
but not NELL2, while group B tumours show the opposite staining pattern.
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Medulloblastoma
Medulloblastoma is the most common malignant pediatric brain tumour, but may also occur in younger adults. More than any other brain tumour, medulloblastoma has become paradigmatic for the power of modern high throughput technology to allow subclassification and assignment to putative oncogenic pathways presumably reflecting different cells of origin or stages of neural development.
Current approaches define four subgroups which, however, may be further subclassified: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4, each characterized by differential expression profiles and characteristic patterns of age of onset, localization and outcome. [66] [67] [68] [69] Most importantly, the pediatric neurooncology community came up with a consensus paper supported by leading groups across the world agreeing to this classification approach. 70 An immediate clinical consequence of this ground-breaking work has been that most new studies in North America and Europe account for the fact that WNT-driven medulloblastoma patients have an excellent overall survival with current therapy regimens, so it is now being tested whether it is safe to reduce the dose of RT for these patients. The first clinical experience with the smoothened inhibitor vismodegib as a targeted approach to medulloblastoma demonstrated a dramatic, albeit short-lived response. 71 However, larger studies on less-heavily pre-treated patients are forthcoming using either vismodegib or LDE-225 and at first 
Outlook
Tremendous progress has been made in the molecular classification of primary brain tumours. In the case of MGMT promoter methylation in glioblastoma in the elderly and 1p/19q co-deletions in anaplastic oligodendroglial tumours, molecular markers determine clinical decision making as of 2012, based on few practice-changing academic trials. 13, 14, 24, 25 Depending on the outcome of ongoing phase II and III trials of novel targeted agents in newly diagnosed and recurrent glioblastoma, biomarkers to predict resistance or sensitivity to angiogenesis inhibition will move into focus, both in tumour tissue and in peripheral blood. In medulloblastoma, molecular subclassification is now used for selecting targeted agents depending on the dominant oncogenic pathway. Meanwhile, highthroughput analyses at genetic, epigenetic and expression levels have demonstrated their value in classifying brain tumours and prognosticating outcome. These techniques may soon become more widely available, easier to standardise and less subject to bias, than single marker assessments, e.g., current ways of determining the MGMT status, and may soon become more cost-effective, too.
Accordingly, we predict that the current histology-dominated diagnostic assessment of brain tumours will be increasingly supplemented by molecular diagnostic tests, which eventually may be gradually replaced by high throughput profiling techniques, including array-based approaches and nextgeneration sequencing. This progress in molecular diagnostics will help to improve the precision of histological diagnoses, to select appropriate therapeutic measures, and to enrich patient populations for clinical trials.
Yet, it is also important to realize that array-based approaches will not completely supplant targeted
analyses. There are still instances where diagnoses are being rendered on miniscule portions of tissue obtained by biopsy or from the very edge of infiltrating gliomas where the nature of the lesion, tumour or not, is uncertain, and high-throughput techniques might not be as helpful or simply cannot be applied due to limited tissue availability.
In addition to the complex interdisciplinary dialogue required for optimized clinical decision making, the technical challenges associated with assessing molecular markers in brain tumour patients further support the call for centralized care of patients with relatively rare tumours, for whom an increasing repertoire of novel treatment options is currently being made available.
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